
Joint Ventures: CAR-T, Early Diagnosis Reshape Scleroderma at EULAR 2026
6/24/2026
0:00
13:18
The therapeutic framework for systemic sclerosis is undergoing a fundamental reorientation, moving away from managing visible fibrotic sequelae toward targeting the autoantibody-driven mechanisms believed to initiate and propagate disease.
On a recent episode of Joint Ventures recorded live at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress in London, host Jack Arnold, MBBS, PhD, of the University of Leeds, spoke with Vishal Kakkar, MD, also of the University of Leeds and a specialist in scleroderma, about the most consequential data emerging from the congress.
More episodes from "HCPLive Podcasts"



Don't miss an episode of “HCPLive Podcasts” and subscribe to it in the GetPodcast app.








